191 related articles for article (PubMed ID: 37182801)
1. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
4. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
5. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
6. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
[TBL] [Abstract][Full Text] [Related]
8. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
9. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
10. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
11. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
Duke ES; Barone AK; Chatterjee S; Mishra-Kalyani PS; Shen YL; Isikwei E; Zhao H; Bi Y; Liu J; Rahman NA; Wearne E; Leighton JK; Stephenson M; Ojofeitimi I; Scepura B; Nair A; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Oct; 28(19):4173-4177. PubMed ID: 35679021
[TBL] [Abstract][Full Text] [Related]
13. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.
Sherman EJ; Dunn LA; Schöder H; Ho AL; Baxi SS; Ghossein RA; Haque SS; Sima C; Tuttle RM; Pfister DG
Cancer; 2019 Sep; 125(17):2984-2990. PubMed ID: 31174237
[TBL] [Abstract][Full Text] [Related]
15. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
16. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
17. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
[No Abstract] [Full Text] [Related]
18. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
Anderson RT; Linnehan JE; Tongbram V; Keating K; Wirth LJ
Thyroid; 2013 Apr; 23(4):392-407. PubMed ID: 23294230
[TBL] [Abstract][Full Text] [Related]
19. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
[TBL] [Abstract][Full Text] [Related]
20. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
